Race Oncology
Race Oncology is a specialty pharmaceutical company focused on rediscovering and rescuing life-saving drugs that can deliver early commercial milestones. Race Oncology’s first asset is Bisantrene, a small molecule Chemotherapy drug that has been evaluated clinically for Acute Myeloid Leukaemia (AML).
ASX Announcements
| Date | Title | |
|---|---|---|
| 13/11/2018 | Replacement-Change in substantial holding notice | Download |
| 12/11/2018 | Change in substantial holding | Download |
| 12/11/2018 | Change of Director's Interest Notice-Dr William Garner | Download |
| 01/11/2018 | Response to ASX Price Query | Download |
| 01/11/2018 | Race appoints Biosynergy to pursue Bisantrene licensing | Download |
| 26/10/2018 | September 2018 Quarterly Report | Download |
| 18/10/2018 | Notice of Annual General Meeting/Proxy Form | Download |
| 18/10/2018 | Annual Report to Shareholders | Download |
| 01/10/2018 | RAC appoints US consultant to drive partnering, investment | Download |
| 01/10/2018 | Expiry of Unlisted Options | Download |
ASX: RAC
Price
Latest News
Race appoints BioSynergy to pursue Bisantrene licensing
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy
Compelling value upside for Race
A new report by Independent Investment Research suggests that Australian biotech Race Oncology
Finance News Network interviews CEO Peter Molloy
CEO Peter Molloy spoke with Finance News Network about Bisantrene and Race Oncology’s
Don't miss important updates
Get the latest news & announcement and stay up-to-date.